JP2023502108A5 - - Google Patents

Info

Publication number
JP2023502108A5
JP2023502108A5 JP2022528625A JP2022528625A JP2023502108A5 JP 2023502108 A5 JP2023502108 A5 JP 2023502108A5 JP 2022528625 A JP2022528625 A JP 2022528625A JP 2022528625 A JP2022528625 A JP 2022528625A JP 2023502108 A5 JP2023502108 A5 JP 2023502108A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cdr
cancer
ror2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022528625A
Other languages
English (en)
Japanese (ja)
Other versions
JP7734661B2 (ja
JP2023502108A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061130 external-priority patent/WO2021102055A1/en
Publication of JP2023502108A publication Critical patent/JP2023502108A/ja
Publication of JP2023502108A5 publication Critical patent/JP2023502108A5/ja
Application granted granted Critical
Publication of JP7734661B2 publication Critical patent/JP7734661B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022528625A 2019-11-18 2020-11-18 抗ror-2抗体および使用方法 Active JP7734661B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962936900P 2019-11-18 2019-11-18
US62/936,900 2019-11-18
PCT/US2020/061130 WO2021102055A1 (en) 2019-11-18 2020-11-18 Anti-ror-2 antibodies and methods of use

Publications (3)

Publication Number Publication Date
JP2023502108A JP2023502108A (ja) 2023-01-20
JP2023502108A5 true JP2023502108A5 (cg-RX-API-DMAC7.html) 2023-11-21
JP7734661B2 JP7734661B2 (ja) 2025-09-05

Family

ID=75981012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528625A Active JP7734661B2 (ja) 2019-11-18 2020-11-18 抗ror-2抗体および使用方法

Country Status (11)

Country Link
US (1) US12643947B2 (cg-RX-API-DMAC7.html)
EP (1) EP4061848A4 (cg-RX-API-DMAC7.html)
JP (1) JP7734661B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220113951A (cg-RX-API-DMAC7.html)
CN (1) CN116018353A (cg-RX-API-DMAC7.html)
AU (1) AU2020388577A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009611A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161617A1 (cg-RX-API-DMAC7.html)
IL (1) IL293026A (cg-RX-API-DMAC7.html)
MX (1) MX2022005949A (cg-RX-API-DMAC7.html)
WO (1) WO2021102055A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011494A (es) * 2019-03-26 2021-12-15 Univ California Células t modificadas con el receptor de antígeno quimérico (t car) para el tratamiento de cánceres hematológicos y tumores sólidos.
CA3244077A1 (en) * 2022-02-25 2023-08-31 Bioatla, Inc. CANCER TREATMENT WITH A CONDITIONALLY ACTIVE ANTI-ROR2 ANTIBODY-DRUG CONJUGATE
EP4642808A2 (en) * 2022-12-30 2025-11-05 The Regents of the University of California Anti-ror-2 antibodies and methods of use
EP4739347A1 (en) 2023-07-07 2026-05-13 Solve Therapeutics, Inc. Conjugates of drug units and targeting units and precursor compounds thereof
CN121181696A (zh) * 2024-06-21 2025-12-23 深圳大学 一种治疗肿瘤的抗体及其应用
WO2026011121A1 (en) 2024-07-03 2026-01-08 Solve Therapeutics, Inc. Anti-ror2 antibody-drug conjugates
WO2026128025A2 (en) 2024-07-03 2026-06-18 Solve Therapeutics, Inc. Anti-ror2 antibody-radionuclide conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR062709A1 (es) * 2006-09-08 2008-11-26 Genentech Inc Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt
GB201506407D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CN109311982A (zh) 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
EP4122958A1 (en) 2016-05-13 2023-01-25 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3026151A1 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
SG10202107808SA (en) * 2017-01-18 2021-08-30 F1 Oncology Inc Chimeric antigen receptors against axl or ror2 and methods of use thereof
US11447546B2 (en) * 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2

Similar Documents

Publication Publication Date Title
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
JP2022518925A5 (cg-RX-API-DMAC7.html)
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2024023228A5 (cg-RX-API-DMAC7.html)
JP2022507679A (ja) Her2/pd1二重特異性抗体
TWI916327B (zh) 結合pd-1的抗體
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2021512614A5 (cg-RX-API-DMAC7.html)
JP2021519072A5 (cg-RX-API-DMAC7.html)
JP2019509023A (ja) Ror2抗体組成物及び関連する方法
CN103998468A (zh) 抗原结合蛋白及其用作治疗癌症的定位产品的用途
WO2018119118A4 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
TWI867218B (zh) 靶向her2的抗原結合建構體及用途
JP2021520201A5 (cg-RX-API-DMAC7.html)
JP2024508808A5 (cg-RX-API-DMAC7.html)
JP2021512604A5 (cg-RX-API-DMAC7.html)
CA3240254A1 (en) Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
CN105452297B (zh) mAb 2抗-Met抗体
CA3229160A1 (en) Bispecific tetravalent antibody targeting egfr and her3
JP7698581B2 (ja) 抗メソテリン抗体、抗cd3抗体又は抗egfr抗体を含む融合タンパク質、それを含む二重特異性又は三重特異性抗体、及びその使用
Mazor et al. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5 (Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts
AU2021446021A1 (en) Anti-bcam antibody or antigen-binding fragment thereof
JP2023103439A (ja) 固形腫瘍の治療に有益な抗体およびその抗体-薬物コンジュゲート並びにこれらを含む抗がん剤
CN114539420B (zh) 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
JP2024517760A (ja) 抗5t4抗体及びその使用